source
- SonoThera secures $186 million to advance non-viral gene-therapy platformSonoThera, the winner of the Endpoints 11 2026 competition, announced a fresh financing round to push its non-viral gene-therapy technology forward. The company raised a total of $186 million, wit…
- ADARx prices $446.3 million Nasdaq debut, boosting biotech IPO waveADARx Pharmaceuticals, a RNA interference focused biotech, announced pricing of its initial public offering at $446.3 million on Nasdaq. The offering was upsized, reflecting strong investor demand…